Investigation for efficacy and safety of tau PET ligand [18F]PM-PBB3

Trial Profile

Investigation for efficacy and safety of tau PET ligand [18F]PM-PBB3

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 22 Jan 2018

At a glance

  • Drugs APN-1607 (Primary)
  • Indications Alzheimer's disease; Corticobasal degeneration; Mild cognitive impairment; Progressive supranuclear palsy
  • Focus Pharmacokinetics
  • Most Recent Events

    • 22 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top